Delay is harm. In cardiovascular prevention, time lost is benefit lost.
New ESC guidelines introduce 'extreme cardiovascular risk' classification for patients with recurrent events or aggressive atherosclerosis, targeting LDL <40 mg/dL. Guidelines shift from stepped treatment to 'strike early and strong' strategy, using combination therapy from onset to achieve targets faster in high-risk patients.
- New ESC guidelines introduce 'extreme cardiovascular risk' category with LDL target <40 mg/dL
- Guidelines shift from stepped treatment to 'strike early and strong' combination therapy from onset
- Bempedoic acid added as option for statin-intolerant patients, reducing LDL by 15–25%
- Very high-risk patients maintain LDL target <55 mg/dL with ≥50% reduction from baseline
- Lipoprotein(a) elevated as key residual risk modifier even when LDL appears controlled
European Cardiology Society updates guidelines introducing 'extreme cardiovascular risk' category with LDL cholesterol target <40 mg/dL, advocating earlier and more intensive treatment strategies over traditional stepped approaches.
The European Society of Cardiology has redrawn the map of cardiovascular risk. In its updated guidelines, the organization has introduced a new category it calls 'extreme cardiovascular risk'—a designation that applies to patients whose arteries are failing them repeatedly, despite treatment, or whose atherosclerosis is moving with unusual aggression. For these patients, the target for LDL cholesterol has been set at less than 40 mg/dL, a threshold that would have seemed radical just years ago.
Drs. Rosa Fernández Olmo and Alberto Cordero, who coordinate the Spanish Cardiology Society's lipid disorders and residual risk group, describe this as one of the most significant shifts in the updated guidance. But the new target is only part of a larger philosophical change. The guidelines are abandoning the old stepped approach to treatment—the cautious, gradual intensification that has long defined cardiology practice. Instead, they advocate for what researchers call 'strike early and strong': aggressive combination therapy from the very beginning, particularly for patients at highest risk and especially after an acute coronary event. The evidence, Fernández Olmo and Cordero explain, is clear. When LDL cholesterol is reduced early, intensively, and sustained over time, cardiovascular events decline and patient outcomes improve.
This shift reflects a frustration that runs through modern cardiology. Despite decades of treatment options, LDL cholesterol control remains inadequate across patient populations, even among those with established cardiovascular disease. Contemporary registries show the problem plainly: while combination therapy—typically a statin paired with ezetimibe—has become more common, most patients still fall short of guideline targets. The real obstacle is no longer the absence of effective drugs. It is therapeutic inertia: doctors intensify treatment too slowly, check cholesterol levels too infrequently, and accept numbers that should no longer be considered acceptable in high-risk patients.
For patients classified as very high risk—those with established atherosclerotic disease such as prior heart attack, stroke, or peripheral artery disease, as well as those with diabetes and organ damage or advanced chronic kidney disease—the guidelines maintain an LDL target of less than 55 mg/dL, accompanied by at least a 50 percent reduction from baseline. These are not aspirational figures. They are therapeutic objectives directly linked to preventing new cardiovascular events. The guidelines emphasize that these targets must be reached quickly and maintained over the long term.
The new extreme risk category represents a conceptual leap. It encompasses patients with recurrent cardiovascular events despite treatment, those with disease affecting multiple vascular beds, and those whose atherosclerosis shows particularly aggressive features. The less-than-40 target for this group reflects a shift in thinking: the goal is no longer simply to prevent a first recurrent event but to slow an especially active and unstable atherosclerotic disease.
Bempedoic acid has been added to the therapeutic arsenal, offering particular value for patients who cannot tolerate statins or who fail to reach targets with conventional treatment. Unlike statins, bempedoic acid is a prodrug that does not activate in skeletal muscle, substantially reducing the risk of muscle pain. Studies show it reduces LDL by 15 to 25 percent and decreases cardiovascular events in statin-intolerant patients. Its real strength may lie in enabling combination strategies and intensifying treatment in patients for whom therapeutic options were previously limited.
The guidelines also elevate the importance of other cardiovascular risk modifiers: lipoprotein(a), obesity, inflammation, and metabolic disease. Lipoprotein(a) is gaining particular attention because it identifies patients with elevated residual atherosclerotic risk even when LDL appears controlled. The updated guidance also dedicates space to historically undertreated populations—cancer patients and those with HIV—who carry high cardiovascular risk but have often been left out of prevention conversations. Modern cardiovascular prevention, the guidelines suggest, must be earlier, more personalized, and far less tolerant of LDL levels that were considered acceptable just a few years ago.
Notable Quotes
The evidence shows that reducing LDL cholesterol early, intensively, and sustained over time decreases cardiovascular events and improves outcomes.— Drs. Rosa Fernández Olmo and Alberto Cordero, Spanish Cardiology Society
The main problem is no longer lack of treatment, but therapeutic inertia: we intensify too late, review too late, and accept LDL levels that should no longer be acceptable in high-risk patients.— Drs. Fernández Olmo and Cordero
The Hearth Conversation Another angle on the story
Why introduce a new category at all? Couldn't the 'very high risk' group simply have tighter targets?
Because the patients in this extreme category are different. They're not just at high risk—they're failing treatment. They have recurrent events, multiple vascular beds involved, aggressive disease. The old categories didn't capture that reality.
So the less-than-40 target is saying something specific about what these patients need?
Exactly. It's acknowledging that we're not trying to prevent a first event anymore. We're trying to stop a disease that's already proven it won't quit. That requires a different intensity of approach.
The 'strike early and strong' idea—doesn't that risk overtreatment in people who might do fine with gentler approaches?
That's the old thinking. The evidence shows that waiting, stepping up slowly, costs time and clinical benefit. In cardiovascular prevention, delay is harm. And we have safe, effective tools now. The real risk is treating too late and too timidly.
What about bempedoic acid? It sounds like a workaround for people who can't take statins, not a breakthrough.
It's both. For statin-intolerant patients, it's genuinely life-changing—they finally have a real option. But it also lets us combine therapies in ways we couldn't before. That's where the breakthrough is.
You mentioned lipoprotein(a). Why is that suddenly important?
Because LDL can look controlled and patients still have events. Lp(a) explains some of that gap. It's residual risk hiding in plain sight. The guidelines are saying we need to see it, measure it, and act on it.
What's the biggest barrier to actually using these guidelines?
Habit. Doctors are trained to step up slowly. Patients expect gradual change. But the guidelines are saying that caution is now the riskier choice. That's a hard message to live.